Marcella Tazzari

Dr. Marcella Tazzari

Unit of Immunotherapy - Cell Therapy and Biobank, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBS. Di Blasio
S. Di Blasio
GWG. F. van Wigcheren
G. F. van Wigcheren
ABA. Becker
A. Becker
ADA. van Duffelen
A. van Duffelen
MGMark A.J. Gorris
Mark A.J. Gorris
CFCarl Figdor
Carl Figdor
The tumour microenvironment (TME) forms a major obstacle in effective cancer treatment and for clinical success of immunotherapy. Conventional co-cultures have shed light onto multiple aspects of cancer immunobiology, but they are limited by the lack of physiological complexity. We develop a human organotypic skin melanoma culture (OMC) that allows real-time study of host-malignant cell interactions within a multicellular tissue architecture. By co-culturing decellularized dermis with keratinocytes, fibroblasts and immune cells in the presence of melanoma cells, we generate a reconstructed TME that closely resembles tumour growth as observed in human lesions and supports cell survival and function. We demonstrate that the OMC is suitable and outperforms conventional 2D co-cultures for the study of TME-imprinting mechanisms. Within the OMC, we observe the tumour-driven conversion of cDC2s into CD14+ DCs, characterized by an immunosuppressive phenotype. The OMC provides a valuable approach to study how a TME affects the immune system.

10 August 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Silvia StacchiottiSilvia Stacchiotti
Silvia Stacchiotti
MPmaria pantaleo
maria pantaleo
TNTiziana Negri
Tiziana Negri
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
MTMarcella Tazzari
Marcella Tazzari
PCPaolo G. Casali
Paolo G. Casali
Purpose:To report on imatinib mesylate (IM) in patients with metastatic dermatofibrosarcoma protuberans (DFSP)/ fibrosarcomatous (FS)-DFSP and on the impact of the treatment on tumor biology Experimental Design:Ten consecutive patients treated with IM from 2007 to 2015 for a metastatic relapse from DFSP/FS-DFSP were identified. FISH analysis for COL1A1-PDGFb was performed. Two IM-treated and 4 naïve FS-DFSP were transcriptionally profiled by RNAseq on HiScanSQ platform. Differential gene expression was analyzed with edgeR (Bioconductor), followed by hierarchical clustering and Principal Component Analysis (PCA). Results:All cases featured fibrosarcomatous in the metastasis and retained the COL1A1-PDGFB. Best RECIST response was: 8 PR, 1 SD, 1 PD. Median PFS was 11 months. Five patients received surgery after IM and all relapsed. IM was restored in 4 patients with a new response. After IM, the most up-regulated genes included those encoding for immunoglobulins and those affecting functions and differentiation of endothelial cells. Pathway enrichment analysis revealed up-regulation in genes involved in antigen processing and presentation, NK mediated cytotoxicity, and drug and xenobiotics metabolism. Conversely, a significant down-regulation of kinase signaling pathways was detected. Conclusions:All metastatic cases were fibrosarcomatous. Most patients responded to IM but PFS was shorter than reported in published series which included both DFSP and FS/DFSP. All patients operated after IM had a relapse, suggesting that IM cannot eradicate metastatic cases and that the role of surgery is limited. Transcriptional profile of naïve and post-treatment samples pointed the contribution of immune infiltrates in sustaining the response to IM.

1 June 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
Silvia StacchiottiSilvia Stacchiotti
Silvia Stacchiotti
MPmaria pantaleo
maria pantaleo
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
GDG.P. Dagrada
G.P. Dagrada
TNT. Negri
T. Negri
PCP.G. Casali
P.G. Casali

Verified
Journal Article
Open access
PDF file
MTMarcella Tazzari
Marcella Tazzari
LBLaura Bergamaschi
Laura Bergamaschi
Alessandro De VitaAlessandro De Vita
Alessandro De Vita
PCPaola Collini
Paola Collini
MBMarta Barisella
Marta Barisella
VVViviana Vallacchi
Viviana Vallacchi
Soft tissue sarcomas (STSs) are a family of rare malignant tumors encompassing more than 80 histologies. Current therapies for metastatic STS, a condition that affects roughly half of patients, have limited efficacy, making innovative therapeutic strategies urgently needed. From a molecular point of view, STSs can be classified as translocation-related and those with a heavily rearranged genotype. Although only the latter display an increased mutational burden, molecular profiles suggestive of an “immune hot” tumor microenvironment are observed across STS histologies, and response to immunotherapy has been reported in both translocation-related and genetic complex STSs. These data reinforce the notion that immunity in STSs is multifaceted and influenced by both genetic and epigenetic determinants. Cumulative evidence indicates that a fine characterization of STSs at different levels is required to identify biomarkers predictive of immunotherapy response and to discover targetable pathways to switch on the immune sensitivity of “immune cold” tumors. In this review, we will summarize recent findings on the interplay between genetic landscape, molecular profiling and immunity in STSs. Immunological and molecular features will be discussed for their prognostic value in selected STS histologies. Finally, the local and systemic immunomodulatory effects of the targeted drugs imatinib and sunitinib will be discussed.

14 June 2009 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
ALAlvaro Lladser
Alvaro Lladser
KLKarl Ljungberg
Karl Ljungberg
HTHelena Tufvesson
Helena Tufvesson
MTMarcella Tazzari
Marcella Tazzari
ARAnna-Karin Roos
Anna-Karin Roos
RKRolf Kiessling
Rolf Kiessling

1 February 2017 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MTMarcella Tazzari
Marcella Tazzari
VIValentina Indio
Valentina Indio
BVBarbara Vergani
Barbara Vergani
LCLoris De cecco
Loris De cecco
FRFrancesca Rini
Francesca Rini
CCChiara Castelli
Chiara Castelli